{
  "id": 19276448,
  "title": "FDA Warns GLP-1s May Increase Risk of Sudden Blindness",
  "url": "https://urgent.news/2026/11/10/fda-warns-glp-1s-may-increase-risk-of-sudden-blindness",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T03:30:00.000Z",
  "source": {
    "name": "Slashdot",
    "slug": "slashdot",
    "url": "https://science.slashdot.org/story/26/11/09/231215/fda-warns-glp-1s-may-increase-risk-of-sudden-blindness"
  },
  "original_language": "en",
  "account": "The Food and Drug Administration (FDA) issued a warning on Monday that certain GLP-1 drugs may be linked to a heightened risk of nonarteritic anterior ischemic optic neuropathy (NAION), a condition that can result in sudden, permanent blindness in one eye. This advisory applies to all currently marketed GLP-1 medications, including Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound, as well as older diabetes drugs. GLP-1 drugs, which are used to manage diabetes and aid weight loss, are believed to potentially increase the likelihood of NAION, though the exact mechanism remains unknown. Risk factors for NAION overlap with those often seen in individuals taking GLP-1 medications, such as Type 2 diabetes, obesity, sleep apnea, and hypertension. The FDA's decision stems from a 2024 study published in JAMA Ophthalmology, which indicated that diabetes patients prescribed semaglutide were four times more likely to develop NAION than those not on the drug. The agency conducted a thorough review of adverse event reports and analyzed data from clinical trials, finding that cases of NAION have been reported for all currently marketed GLP-1 drugs. Despite the FDA's inability to determine how the drugs might raise the risk, the agency emphasizes that patients and caregivers should be informed of this potential risk associated with GLP-1 use.",
  "summary": "An anonymous reader quotes a report from NBC News: The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness. The condition, called nonarteritic anterior ischemic optic neuropathy, or NAION, affects the optic nerve, which carries signals from the eye to the brain. When blood flow to the nerve is reduced…",
  "key_points": [
    "FDA warns GLP-1 drugs may increase risk of sudden blindness.",
    "Study shows diabetes patients on semaglutide four times more likely to develop NAION."
  ],
  "editors_take": "The FDA advisory introduces a significant safety concern for patients using popular weight loss and diabetes medications, potentially complicating the risk-benefit profile of the entire GLP-1 drug class.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}